Top broker says buy CSL shares right now for 36% upside

The ASX 200 healthcare blue chip fell to a new 52-week low of $244.37 in early trading on Tuesday.

| More on:
A hipster-looking man with bushy beard and multiple arm tattoos sits on the floor against a sofa reading a tablet with his hand on his chin as though he is deep in thought.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) shares fell to a new 52-week low of $244.37 apiece in early trading on Tuesday.

The ASX 200 healthcare giant is currently trading at $248.93 a share, up 1.04%.

The S&P/ASX 200 Index (ASX: XJO) is down 1.32% at the time of writing.

One top broker says CSL is ripe for buying, with 36% upside potential over the next 12 months.

Broker backs CSL shares for major upside over next year

Top broker Morgan Stanley says CSL can go 36% higher over the next 12 months.

The broker has an overweight rating on the healthcare stock and a $334 price target.

In The Australian today, Morgan Stanley analyst Sean Laaman says:

If EPS momentum can be further enhanced through PBM execution, our valuation and price target may prove conservative.

On the back of PBM execution/articulation, the perceived risk regarding Injectafer generics competition may diminish.

Laaman notes that CSL shares have underperformed the market in recent times.

In the year to date, CSL stock has fallen 13% while the ASX 200 has fallen 0.12%.

The reasons for this are "now well understood".

He explains:

We think this is due to recovery to pre-pandemic plasma GM in FY26-FY28 has been slower than we anticipated, FcRn disruption in CIDP possible in FY25, and generic competition nears for V4's Injectafer in Europe.

Morgans is also backing CSL shares for significant share price growth.

As my Fool colleague James reports, Morgans has CSL on its 'best ideas' list.

The broker has an add rating on CSL and a $328.28 share price target.

Morgans says:

While shares have struggled of late, we continue to view CSL as a key portfolio holding and sector pick, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average.

Motley Fool contributor Bronwyn Allen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no positions in any of the companies mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on 52-Week Lows

A businesswoman ponders why her boat is sinking in the ocean.
52-Week Lows

Lake Resources share price falls 7% to new 52-week low amid second strike AGM vote

Chair Stu Crow described "a year of significant progress" amid an 80% decline in the share price in 2023.

Read more »

A man sits uncomfortably at his laptop computer in an outdoor location at a table with trees in the background as he clutches the back of his neck with a wincing look on his face.
Materials Shares

Why did the Core Lithium share price just hit a 2-year low?

Top broker Goldman Sachs says falling lithium commodity prices may hit Core Lithium particularly hard.

Read more »

a mine worker holds his phone in one hand and a tablet in the other as he stands in front of heavy machinery at a mine site.
Resources Shares

Why has the South32 share price tanked 4% to a 2-year low today?

It's been a bad day to own South32 shares...

Read more »

A guys points his fingers down.
52-Week Lows

Down 24% in a month: Is this director buying the dip on IGO shares?

The IGO share price hit a new 52-week low of $9.19 today.

Read more »

Red arrow going down and symbolising a falling share price.
Materials Shares

Why has the Allkem share price just hit a new 52-week low?

Allkem shares are going the opposite way to the stock market today.

Read more »

A young woman with long brown hair opens her green eyes widely expressing surprise.
52-Week Lows

Guess which ASX All Ords share is crashing 34% to a 52-week low

This biopharmaceutical company's shares are being hammered on Wednesday. But why?

Read more »

A young man goes over his finances and investment portfolio at home.
52-Week Lows

Guess which ASX 200 stock just crashed below 2016 prices?

These shares just hit an ALL-TIME low. Could it be time to pick up the bargain of the century?

Read more »

A businesswoman ponders why her boat is sinking in the ocean.
Materials Shares

Lake Resources share price drops 6% as investors digest latest news on Kachi

The Lake Resources share price fell back to January 2021 levels today.

Read more »